Minerva Neurosciences Inc. (NASDAQ:NERV) shares traded down 0% during mid-day trading on Friday . The company traded as low as $10.51 and last traded at $10.66, with a volume of 72,026 shares changing hands. The stock had previously closed at $10.66.

A number of research analysts have issued reports on the company. Zacks Investment Research raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Thursday. Jefferies Group reissued a “buy” rating and issued a $17.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, June 8th. Finally, JMP Securities boosted their target price on Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th.

The firm’s 50 day moving average price is $9.96 and its 200 day moving average price is $6.74. The firm’s market cap is $298.14 million.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, analysts expect that Minerva Neurosciences Inc. will post ($1.05) earnings per share for the current year.

In other Minerva Neurosciences news, Director David Kupfer bought 55,635 shares of the business’s stock in a transaction dated Tuesday, June 21st. The shares were purchased at an average price of $10.84 per share, for a total transaction of $603,083.40. Following the purchase, the director now directly owns 209,188 shares of the company’s stock, valued at $2,267,597.92. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.